Landogrozumab (LY2495655) is an humanized anti-myostatin monoclonal antibody. Landogrozumab effectively improves muscle volume, hand grip strength and function. Landogrozumab can be used for the research of muscle wasting disease[1].
in vivo
Landogrozumab (3 and 15 mg/kg; i.v. once) affects muscle mass of aged mice with duchenne muscular dystrophy[1].
